Objective: Inflammatory response plays an important role in Parkinson disease (PD). Previous studies have reported an association between human leukocyte antigen (HLA)-DRB1 and the risk of PD. There has also been growing interest in investigating whether inflammation-related genes interact with environmental factors such as smoking to influence PD risk. We performed a pooled analysis of the interaction between HLA-DRB1 and smoking in PD in 3 population-based case-control studies from Denmark and France. Methods: We included 2,056 cases and 2,723 controls from 3 PD studies (Denmark, France) that obtained information on smoking through interviews. Genotyping of the rs660895 polymorphism in the HLA-DRB1 region was based on saliva or blood DNA samples. To assess interactions, we used logistic regression with product terms between rs660895 and smoking. We performed random-effects meta-analysis of marginal associations and interactions. Results: Both carrying rs660895-G (AG vs AA: odds ratio [OR] 5 0.81; GG vs AA: OR 5 0.56; p-trend 5 0.003) and ever smoking (OR 5 0.56, p < 0.001) were inversely associated with PD. A multiplicative interaction was observed between rs660895 and smoking using codominant, additive (interaction parameter 5 1.37, p 5 0.005), and dominant (interaction parameter 5 1.54, p 5 0.001) genetic models without any heterogeneity (I 2 5 0.0%); the inverse association of rs660895-(AG1GG) with PD seen in never smokers (OR 5 0.64, p < 0.001) disappeared among ever smokers (OR 5 1.00, p 5 0.99). Similar interactions were observed when we investigated light and heavy smokers separately. Interpretation: Our study provides the first evidence that smoking modifies the previously reported inverse association of rs660895-G with PD, and suggests that smoking and HLA-DRB1 are involved in common pathways, possibly related to neuroinflammation.
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We previously examined 51 single nucleotide polymorphisms (SNPs) in the HLA-DR region in 2 French case-control datasets. We found that rs660895-G (in the HLA-DRB1 region) showed the strongest association with PD (odds ratio [OR] 5 0.70, 95% confidence interval [CI] 5 0.57-0.87) 7 and did not confirm the previously reported association with the HLA-DRA locus. 6 In the same study, SNP-based imputation of HLA alleles showed an inverse association with the HLA-DRB1*04 allele.
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Rs660895 was also the strongest HLA region hit in a genome-wide association study (GWAS). 8 A British casecontrol study also reported a lower frequency of the HLA-DRB1*04 allele in PD patients than in matched controls, 9 and a Chinese study found a reduced risk of PD associated with the HLA-DRB1*0406 allele. 10 Finally, based on SNPbased imputation of HLA alleles, 2 GWASs showed an inverse association between HLA*DRB1*0404 and PD.
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PD is likely to be caused by a combination of genetic and environmental factors, acting in concert with each other. Whereas smoking increases the risk of many diseases, in particular through inflammatory mechanisms, 12, 13 it has consistently been shown to be inversely associated with PD. 14 It remains unknown, however, whether this robust inverse association is causal or not. Some have argued that it cannot be explained by survival bias or confounding, 15 but reverse causation cannot be discarded as an alternative explanation, due to increasing evidence of a long premotor period. 16, 17 The identification of gene-environment interactions represents a possible approach to better understand the biological mechanisms underlying the association between environmental exposures and disease and to improve causal inference. In our previous study, we showed that the rs660895-PD association was restricted to never smokers (OR 5 0.63, 95% CI 5 0.49-0.81), whereas there was no significant association in ever smokers (OR 5 0.93, 95% CI 5 0.61-1.37); however, the interaction test was not significant at the traditional a level of 0.05 (p 5 0.11), 7 and larger studies are necessary to investigate this interaction. The aims of this study were: (1) to investigate the interaction between rs660895 in the HLA-DRB1 region and smoking in PD in a large population-based casecontrol study conducted in Denmark; and (2) to perform a pooled analysis of the smoking-rs660895 interaction based on individual data from the Danish and aforementioned French datasets.
Materials and Methods

Study Population
The data used for the analyses have been assembled in the Parkinson Disease in Denmark (PASIDA) study, and the French Terre and Partage studies.
THE PASIDA STUDY. This study enrolled idiopathic PD patients treated at 10 neurological treatment centers and identified from the Danish National Hospital Register between 1996 and 2009. Population controls were selected from the Danish Central Population Registry and matched on year of birth, sex, and being alive and free of PD at the time of case identification. Detailed recruitment information was published previously. 18 Briefly, from 2,762 eligible patients, 949 (34%) were excluded due to the following reasons: lack of a PD diagnosis on medical records (n 5 179), declined to participate (n 5 497), and failure to confirm idiopathic PD according to accepted criteria in medical record review (n 5 273). 19 smoked at least 1 cigarette, pipe, or cigar/cheroot per week for at least 6 months. In the French studies, ever (including exand current) smokers are those who had smoked at least 1 cigarette per week for at least 6 months; there were few pipe or cigar/cheroot smokers, and all reported smoking cigarettes too. For all studies, we collected lifetime smoking information, that is, the amount and duration of smoking and changes of smoking behavior, and used this information to calculate total pack-years of cigarette smoking. Only smoking behaviors that occurred prior to the date of the first motor symptom or PD diagnosis in cases and the same index date in matched controls were considered. Information on coffee drinking was available in the PASIDA and Partage studies only. 22 Genotyping DNA was extracted from saliva (PASIDA, Partage) or blood (Terre) samples. PASIDA samples were genotyped for rs660895 using multiplex Taqman allelic discrimination assays (Applied Biosystems, Foster City, CA) according to the manufacturer's protocol. For Terre and Partage samples, rs660895 was included in a microarray that was processed by Integragen ( Evry, France) using Illumina technology and Infinium iSelect custom genotyping. 7 In the Terre study, we previously genotyped with Taqman 3 SNPs that were also present on the microarray; the agreement between the 2 methods was > 99% for the 3 SNPs. All 3 datasets passed quality checks, that is, genotyping efficiency > 95% and accuracy > 99.5%; there was no difference in genotyping call rates between cases and controls. Rs660895 is an intergenic SNP located 32.6kb upstream of HLA-DRB1 (from the nearest transcription start site) that tags the HLA-DRB1*04 allele. Based on chromatin immunoprecipitation sequencing and DNaseI-seq peak data (ENCODE project), this SNP was shown to be located within regulatory regions. 26 
Statistical Analysis
We assessed Hardy-Weinberg equilibrium in controls from each study using Pearson chi-square test. Because there was no DNA for some cases and controls, for each study, we broke the matching and used unconditional logistic regression analysis adjusted for the matching factors (PASIDA: year of birth, sex, and onset/ index age [age at index date]; Terre, Partage: index age, sex, and district of residency) to increase statistical efficiency. We first assessed the marginal associations of rs660895 and ever smoking with PD, and computed ORs and 95% CIs. We also considered family history of PD as a potential confounder. Similar to what has been previously reported in the literature, we analyzed rs660895 using codominant, additive, and dominant genetic models; recessive models were not considered due to the low frequency of homozygotes for the minor allele G.
We then examined the independent and joint effects of ever smoking and rs660895 in each study. In further analyses, we used pack-years of smoking defined as a 3-level variable (never smoker, 18, > 18). 24 The 18 pack-years cutoff was the median among ever smokers in controls in the Terre study. For PASIDA and Partage, the median pack-years among ever smokers in controls was 15 and 12, respectively; we chose the cutoff of 18 to separate light/moderate from the heaviest smokers. We also conducted a sensitivity analysis using 12 pack-years as the cutoff.
Multiplicative interactions between ever smoking and rs660895 were examined by introducing a product term between these variables into the regression model; the interaction parameter is the exponential of the regression coefficient associated with this product term. Interactions were tested on a multiplicative scale, as departure from multiplicativity is expected when at least 1 of the interacting factors is preventive. 27 For analyses of both marginal associations and interactions, we pooled the estimates from the 3 studies using random-effects meta-analysis. 28 We tested for between-study heterogeneity with the chi-square-based Q statistic (deemed significant for p < 0.10) and quantified its extent with I 2 , which ranges from 0% to 100% and represents the proportion of between-study variability ascribed to heterogeneity rather than to chance 29, 30 ; I 2 values of 0 to 24% suggest little heterogeneity, 25 to 49% reflect moderate heterogeneity, 50 to 74% reflect large heterogeneity, and >75% reflect very large heterogeneity. Lastly, we assessed the association between rs660895 and smoking among cases and controls separately using unconditional logistic regression adjusted for onset/index age, sex, and matching factors in each study, and again pooled the 3 estimates using random-effects meta-analysis. Case-only studies have been shown to be statistically more powerful than case-control studies when assessing gene-environment interactions assuming that the geneenvironment independence assumption holds, that is, that rs660895 is not associated with smoking among controls. 31 In sensitivity analyses, we checked whether there was an interaction between rs660895 and coffee drinking and whether adjusting for coffee drinking modified our results for the rs660895-smoking interaction.
All analyses were performed using SAS v9.4 (SAS Institute, Cary, NC) and Stata v14.1 (Stata Corporation, College Station, TX). The distribution of rs660895 genotypes was very similar in the controls from the 2 French studies. As expected, compared with control subjects, PD patients were more likely to be male, to report a positive family history of PD, and to have never smoked (see Table 1 ). Supplementary Table 1 shows the cross tabulation of smoking and rs660895 in cases and controls from each study.
Power Calculation
In each study and in the pooled analysis, ever smoking was inversely associated with PD (pooled OR 5 0.56, 95% CI 5 0.49-0.64, p < 0.001; Table 2 ), with a dose-effect relation (p for trend < 0.001) and without any heterogeneity across studies (I 2 5 0.0%).
Similar to what we reported previously, 7 we observed an Supplementary Table 2 shows analyses of the interaction between smoking and rs660895 in each study and Table 3 shows results of the pooled analysis. In PASIDA, the interaction between ever smoking and rs660895 was statistically significant, no matter which genetic model was considered. Under the dominant model, the inverse association between the rs660895-(AG1GG) genotypes and PD in never smokers (OR 5 0.66, 95% CI 5 0.53-0.82) was Table 4 presents the results of case-only and controlonly analyses. Case-only analyses showed a significant and positive association between ever smoking and rs660895-G in cases from PASIDA under all genetic models considered. This pattern was confirmed in pooled analyses without any heterogeneity across studies (I 2 5 0.0% for all genetic models). Among controls, rs660895-G tended to be less frequent among ever smokers than never smokers, but this difference was not significant in any of the studies and in pooled analyses. In both the PASIDA and Partage studies, smoking and coffee drinking were positively associated in controls. There was no significant interaction between rs660895 and coffee drinking (either as a binary variable or in cups per day) in both datasets and in pooled analyses; in addition, the rs660895-smoking interaction remained significant in PASIDA and in pooled analyses after adjusting for coffee consumption (data not shown).
Discussion
In this pooled analysis of individual data from 3 population-based case-control studies, we replicate an inverse association between the rs660895-G allele and PD, and provide the first evidence of a statistically significant interaction between rs660895 and smoking for the risk of PD. The decreased risk of PD in carriers of the rs660895-G allele was restricted to never smokers. We previously reported significant associations of the HLA-DRB1*04 allele and rs660895 with PD, and a strong correlation of rs660895-G with HLA-DRB1*04 (Spearman rho 5 0.77, p < 0.0001) in the French studies included here. 7 These results are in agreement with our findings for rs660895 in the Danish study. Additionally, a British study of 528 cases and 3,000 controls previously reported a lower HLA-DRB1*04 allele frequency in PD patients compared with controls (17% vs 20%, p 5 0.01).
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A subtype of HLA-DRB1*04, HLA-DRB1*0406, which is rare in European but common in Asian populations, was also significantly related to PD in a Han Chinese study of 567 cases and 746 controls (OR 5 0.12, p 5 5 3 10 25 ). 10 An inverse association between HLA*DRB1*0404 and PD was also reported in 2 GWASs using SNP-based imputation. 11 These findings support a role of HLA-DRB1 in the etiology of PD across ethnicities. The HLA-DRB1 gene encodes MHC class II beta chain proteins, which are widely expressed on antigen-presenting cells such as B cells, dendritic cells, and macrophages, including brain microglia. Studies have reported microglial activation in the substantia nigra of PD patients and in animal models, and some have suggested that modulation of microglia-related oxidative stress and inflammation might be a treatment strategy for PD. 34, 35 Observational studies showing an inverse association between nonsteroidal anti-inflammatory drug use and PD also support a role for neuroinflammation in PD. 36 In addition, our findings suggest that the inverse association between HLA*DRB1 and PD is present only in never smokers, and that the inverse association between smoking and PD was less pronounced in carriers of the rs660895-G allele. In analyses based on pack-years of smoking, although interaction ORs tended to be higher for light smokers than heavy smokers, the difference was small and not statistically significant. The finding that the strength of the interaction decreased with increasing exposure to an environmental factor has previously been termed "low exposure-gene effect," with several examples available in the cancer literature 37 ;
according to this pattern, the association between the exposure and the outcome is modified by genetic susceptibility at low exposure levels only, and not at higher levels, thus implying that genetic susceptibility is no longer relevant at high or very high exposure levels. Even larger studies would be needed to further investigate such dosedependent patterns for smoking and HLA-DRB1 in PD. Epidemiologic studies have consistently reported a significant inverse association between smoking and PD, with a dose-effect relation.
14 This has led some researchers to advocate the use of nicotine to prevent or treat PD. 38 There is, however, no consensus yet whether this association is causal or is due to bias or reverse causation, such that those who will develop PD have a diminished nicotinic response allowing them to quit more easily in the prodromal phase of PD; in PASIDA, the risk of developing PD was higher among former smokers who reported that quitting had been easy and who did not use nicotine substitutes. 16 Moreover, older quitting age was strongly associated with nicotine substitute use, whereas age at smoking initiation was not. 16 In the Terre study, ex-smokers were at decreased PD risk even if they stopped smoking 40 years before PD onset. 25 Gene-environment studies may represent a way to improve our understanding of the mechanisms underlying the puzzling association between smoking and PD. Our finding of a multiplicative interaction between HLA-DRB1 and smoking suggests that they are involved in common pathways, possibly related to neuroinflammation; further research is needed to better understand the mechanism underlying the HLA-DRB1-PD association and the interaction with smoking. and adult idiopathic inflammatory myopathies. 43 In MS patients, smoking influenced the proliferation of immune cells in the lung; the magnitude of the increase in alveolar macrophage concentration was associated with HLA-DRB1 alleles. 4 In RA sufferers, smoking and HLA-DRB1*04 interacted to influence their risk of cardiovascular disease 44 ; the hypothesized mechanism was that both HLA-DRB1*04 and smoking enhanced T-cell activation in the lung, which may lead to inflammatory processes in the endothelial cells of the vessel walls and subsequent development of cardiovascular disease. Regarding lymphoma, a recent study showed a positive association with HLA-DRB1 shared epitope alleles (including HLA-DRB1*04) as well as a positive additive interaction between HLA-DRB1 shared epitope alleles and smoking, such that there was no association with smoking in subjects without shared epitope alleles and a significant positive association in those who carried 2 shared epitope alleles. 42 Smoking induces the release of intracellular antigens, and the authors hypothesized that shared epitopecontaining HLA-DRB1 variants may facilitate the presentation of these antigens to helper T cells and induce B-cell chronic activation, which may increase the risk of abnormal proliferation. 42 Interestingly, a meta-analysis showed PD patients to have a 24% reduced risk of leukemia and lymphoma. 45 This finding is in agreement with associations in opposite directions for HLA-DRB1 with PD and lymphoma; although it is unclear how smoking and HLA-DRB1 may interact at the biological level, the observation of interactions in opposite directions in both diseases, one characterized by cell proliferation and the other by neuronal death, deserves further investigation. Lastly, smoking and HLA-DRB1 have also been reported to interact in adult idiopathic inflammatory myopathies. 43 Our study has several strengths, including its large size and study design (pooled analysis of individual data from 3 population-based studies) that provided us with sufficient statistical power to identify an interaction of the size previously reported 7 or even weaker. In case-only analyses, rs660895 was associated with smoking among cases and the assumption of gene-environment independence among controls was met. As studies were population-based, controls were representative of the underlying population from which the cases arose. In addition, in each study, participants were ethnically homogeneous and of European ancestry. The diagnosis of PD was clinically confirmed by neurologists in the 2 French studies, and by careful systematic review of complete medical records in PASIDA. Finally, the effect size of ever smoking was consistent with that reported in a previous meta-analysis of 67 studies (OR 5 0.64, 95% CI 5 0.60-0.69). 32 However, there are also limitations.
Although rs660895-G tags the HLA-DRB1*04 allele, we cannot provide more detailed information about allele subtypes and haplotypes, as additional SNPs were not typed. In addition, the recruitment of PD patients includes both incident and prevalent cases, but stratifying by disease duration produced the same results, making survival bias unlikely (data not shown). Finally, residual confounding due to unmeasured factors cannot be ruled out; however, under gene-environment independence in the population, it has been shown that only unmeasured confounders that also interact with the gene under investigation may bias estimates of gene-environment interactions. 46 In our analyses, coffee did not interact with rs660895-G for the risk of PD, and adjusting for coffee drinking had no impact on our findings. In our previous paper, we also reported that there was no interaction between HLA-DRB1 and professional pesticide exposure in the French dataset (p for interaction 5 0.88).
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Conclusion
The main contribution of this pooled analysis of 3 population-based case-control studies of PD is to show that the inverse association between the rs660895-G allele in the HLA-DRB1 region and PD is restricted to never smokers. This finding suggests that genetic variation in the HLA-DRB1 locus has an effect on the risk of PD in interaction with smoking, and allows generating the hypothesis that HLA-DRB1 and smoking may be involved in common pathways, possibly related to neuroinflammation. To better understand the role of HLA and smoking in PD, further research is needed to elucidate whether a biological basis underlies this interaction and what the mechanisms involved might be.
